I’ll start off by saying this stock should be well over $2.00 which is 400% higher than current stock price. Welcome to the most undervalued and beaten down stock there is…. Opgen
Opgen is fighting antibiotic resistance (amr) which is expected to kill 10M people a year by 2050. They are first in class with innovative tech solutions in combating AMR.
You are buying at the most absolute bottom price at $OPGN. Check any analysis and you will find that you will be entering at a better price than 99.99% of shareholders, including me. (Fuck you)
Shorts fucked us during this major market dip more than they should have. Felt like a hostile takeover in a manner.
Total Market Cap is currently $28.89 million.
Current Assets is $71 million (this is already a 100%+ increase in stock price from current level) prove me wrong…. check the balance sheet as of Dec 31 2021
Before I explain the true market value, understand Opgen owns Curetis and Ares Genetics as subsidiary. That’s why I talk about three companies
True valuation….
1. $24 million (Curetis worth)- what Opgen bought Curetis for during acquisition in 2019. We have since received additional FDA approvals for their unyvero system cartridges for more applications.
-
$54 million – what ares genetics is worth considering we sold 1.1% of the database for $600k this year alone. Estimate is based on entire database. If you look at the recent Edison interview, CEO Oliver, says the database is worth 10s of millions of Euros.
-
$40 million in NOL rollover – we have accumulated $200 million in net operating loss (NOL) which at 20% is $40 million we will save through tax savings in future revenue.
That’s $118 million valuation on what we know and can place a true number on. This does not consider debt owed coming up in April which they are trying to restructure (-15mil) – which puts us at $103million valuation. Edison gave Opgen a very similar valuation in 2020 with less products in this report
Last year we had two offerings totaling $35 million which if exercised would have given both companies combined…. (1/3 ownership) technically speaking. At that valuation, we would be around $105 million which is not too far off my number.
Things I can’t put a value on…. Which could potentially be worth more than any of the above items.
1. Recent FDA Approved Acuitas AMR Gene Panel this basically tells you if certain antibiotics will work on you or not and is Opgens prized possession.
- THE BIG TICKET…. $180 mil pending contract with China – this will send the stock moooning once this is approved “OpGen’s subsidiary Curetis and BCB are parties to an exclusive multi-year distribution agreement for the Unyvero platform and cartridges in China. Once NMPA approves the products, BCB has agreed to contractual minimum purchases of 360 Unyvero systems and more than 1.5 million cartridges cumulative over an 8-year exclusivity period which at current transfer prices between the parties is expected to amount to approximately $180 million in revenue to OpGen at current exchange rates.”
We have already received approval for the unyvero system in China. Just waiting on cartridge approval which should be the easy part.
And… I’m still reading, but this was released yesterday for ares genetics AresID
Hoping for a buyout from Quest Dianostics, QIAGEN, Blitz, Merck of something around $400+ million as I believe the company will do better in bigger hands!
Recent news of Sandoz partnership extended to 2025 as well. Great news!
Ceo Oliver Schacht and Johannes Bacher took $300k+ in stock RSU’s in leu of cash as their bonuses 20 days ago. Seems they think stocks are worth more than than the dollar these days. Major bullish.
They also just restructured a debt repayment rather than giving the European Investment Bank equity via shares. They know shares are worth more at this level than cash at 10% interest.
Always trade after doing due diligence. Penny stocks are always risky, but always have the highest reward. Goodluck.
Any questions? Ask…
Leave a Reply